1 Min Read
March 2 (Reuters) - Beigene Ltd
* Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on continuation option to develop, commercialize BGB-283 outside China Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.